The role of fibrinolysis in the era of primary percutaneous coronary intervention

• References

• 1 Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
• 2 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
• 3 Widimsky P, Wijns W, Fajadet J. et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010; 31: 943-957.
• 4 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI).. Effectiveness of intravenous fibrinolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
• 5 ISIS-2 Collaborative Group.. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
• 6 The GUSTO Investigators.. An international randomized trial comparing four fibrinolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
• 7 GUSTO III investigators.. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-1123.
• 8 ASSENT-2 Investigators.. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
• 9 Szemraj J, Stankiewicz A, Rozmyslowicz-Szerminska W. et al. A new recombinant fibrinolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant. An in-vivo study. Thromb Haemost 2007; 97: 1037-1045.
• 10 Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.. Indications for fibrinolytic therapy in suspected acute myocardialinfarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
• 11 Sinnaeve P, Van de Werf F. Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications. Eur Heart J 2010; 31: 2077-2079.
• 12 Van de Werf F, Barron HV, Armstrong PW. et al. ASSENT-2 Investigators.. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22: 2253-2261.
• 13 Boersma E, Maas ACP, Deckers JW. et al. Early fibrinolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775.
• 14 De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008; 100: 184-195.
• 15 Huisse M-G, Ajzenberg N, Feldman L. et al. Micro-particle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
• 16 Sabatine MS, Cannon CP, Gibson CM. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
• 17 Chen ZM, Jiang LX, Chen YP. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 18 ASSENT-3 Investigators.. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-613.
• 19 Antman EM, Morrow DA, McCabe CH. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-1488.
• 20 Sabatine MS, Morrow DA, Dalby A. et al. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 2007; 49: 2256-2263.
• 21 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
• 22 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous fibrinolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
• 23 Widimsky P, Budesinsky T, Vorac D. et al. Long distance transport for primary angioplasty vs immediate fibrinolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003; 24: 94-104.
• 24 Andersen HR, Nielsen TT, Rasmussen K. et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-742.
• 25 Mehta RH, Bufalino VJ, Pan W. et al. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association‘s Get With the Guidelines program. Am Heart J 2008; 155: 1059-1067.
• 26 Nallamothu BK, Bates ER, Herrin J. et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761-767.
• 27 Kalla K, Christ G, Karnik R. et al. Vienna STEMI Registry Group.. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction. Circulation 2006; 113: 2398-2405.
• 28 Boersma E. Primary Coronary Angioplasty vs.. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27: 779-788.
• 29 Morrison LJ, Verbeek PR, McDonald AC. et al. Mortality and prehospital fibrinolysis for acute myocardial infarction: A meta-analysis. J Am Med Assoc 2000; 283: 2686-2692.
• 30 Bonnefoy E, Lapostolle F, Leizorovicz A. et al. on behalf of the CAPTIM study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-829.
• 31 Steg PG, Bonnefoy E, Chabaud S. et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
• 32 Danchin N, Blanchard D, Steg PG. et al. for the USIC 2000 investigators. Impact of prehospital fibrinolysis for acute myocardial infarction on 1-year outcome. Results from the French nationwide USIC 2000 registry. Circulation 2004; 110: 1909-1915.
• 33 Bonnefoy E, Steg PG, Boutitie F. et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009; 30: 1598-1606.
• 34 De Luca G, Suryapranata H, Zijlstra F. et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42: 991-997.
• 35 De Luca G, Suryapranata H, Ottervanger JP. et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. Circulation 2004; 109: 1223-1225.
• 36 Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction is timing (almost) everything?. Am J Cardiol 2003; 92: 824-826.
• 37 Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005; 95: 100-101.
• 38 Terkelsen CJ, Lassen JF. Treatment delays in ST elevation myocardial infarction. Br Med J 2008; 336: 401-402.
• 39 Pinto DS, Kirtane AJ, Nallamothu BK. et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019-2025.
• 40 Wijns W, Kolh P, Danchin N. et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
• 41 Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators.. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569-578.
• 42 Ellis SG, Tendera M, de Belder MA. et al. FINESSE Investigators.. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-2217.
• 43 Gershlick AH, Stephens-Lloyd A, Hughes S. et al. REACT Trial Investigators.. Rescue angioplasty after failed fibrinolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353: 2758-2768.
• 44 Danchin N, Coste P, Ferrières J. et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118: 268-276.
• 45 Scheller B, Hennen B, Hammer B. et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 634-641.
• 46 Fernandez-Avilés F, Alonso JJ, Castro-Beiras A. et al. Routine invasive strategy within 24 hours of thrombolysis versus ischemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-1053.
• 47 Le May MR, Wells GA, Labinaz M. et al. Combined angioplasty and pharmalogical intervention versus thrombolysis alone in acute myocardial infarction. J Am Coll Cardiol 2005; 46: 417-424.
• 48 Di Mario C, Dudek D, Piscione F. et al. Immediate angioplasty versus standard therapy with rescue angioplasty after fibrinolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371: 559-568.
• 49 Cantor WJ, Fitchett D, Borgundvaag B. et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360: 2705-2718.
• 50 Bohmer E, Hoffmann P, Abdelnoor M. et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after fibrinolysis in acute myocardial infarction in areas with very long transfer distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010; 55: 102-110.
• 51 Huber K, Goldstein P, Danchin N. et al. Network models for large cities: the European experience. Heart 2010; 96: 164-169.
• 52 Borgia F, Goodman SG, Halvorsen S. et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010; 31: 2156-2169.
• 53 Armstrong PW, Gershlick A, Goldstein P. et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010; 160: 30-35.e1.
• 54 Ting HH, Rihal CS, Gersh BJ. et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007; 116: 729-736.
• 55 Lambert L, Brown K, Segal E. et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. J Am Med Assoc 2010; 303: 2148-2155.